Key facts
- This page summarizes Sandesh Mahatme's Form 4 filing for Aeglea BioTherapeutics, Inc. (SYRE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2022, 21:18.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
SEC remarks
Exhibit 24 - Power of Attorney